
Roche posts 7% sales growth in Q3 2026, driven by strong demand for innovative medicines and diagnostics.
Roche reported a 7% sales increase at constant exchange rates in Q3 2026, with a 6% rise for the first nine months, fueled by high demand for key medicines like Xolair, Hemlibra, and Ocrevus. The Pharmaceuticals Division led growth, while Diagnostics...





